AttendMe Owl Logo
AttendMe
Evidence Evolution
CardiologyCardiology

How This Evidence Evolved

SGLT2 Inhibitors in Heart Failure

From glucose-lowering agent to pillar of heart failure therapy

3.1

Timeline

EMPA-REG OUTCOME
2015
DAPA-HF
2019
EMPEROR-Reduced
2020
SOLOIST-WHF
2021
EMPEROR-Preserved
2021
DELIVER
2022
Aiming at harmony (2022 comparison review): ESC 2021
2022
Beghini et al. (2025 review): ESC 2023 HFmrEF/HFpEF
2025
2026 HFrEF guideline review: NICE
2026
Trial
Guideline
Approval
Meta-analysis
Signal

Early observations and pilot data that first suggested a new direction

EMPA-REG OUTCOME compared empagliflozin with placebo added to standard care in type 2 diabetes at high cardiovascular risk. Cardiovascular deaths were 3.7% versus 5.9% (38% relative reduction), and heart-failure hospitalisations were 2.7% versus 4.1% (35% relative reduction). Its primary outcome comprised cardiovascular death, nonfatal myocardial infarction or nonfatal stroke; the primary-outcome hazard ratio was 0.86 (95.02% CI 0.74–0.99; P=0.04 for superiority).
Proof

Landmark RCTs and pivotal trials that established the evidence base

Dedicated trials tested SGLT2 inhibitors in HFrEF with or without diabetes. In DAPA-HF, worsening heart failure or cardiovascular death occurred in 16.3% with dapagliflozin versus 21.2% with placebo over median 18.2 months (HR 0.74, 95% CI 0.65–0.85). EMPEROR-Reduced found cardiovascular death or heart-failure hospitalization in 19.4% versus 24.7% with empagliflozin versus placebo (HR 0.75, 95% CI 0.65–0.86). Both found similar effects regardless of diabetes; this does not establish the precise mechanism.
Extension

Follow-up studies, subgroup analyses, and real-world validation

Trials extended the evidence to higher ejection fractions and recent worsening heart failure. EMPEROR-Preserved enrolled patients with EF >40%: cardiovascular death or heart-failure hospitalization occurred in 13.8% with empagliflozin versus 17.1% with placebo (HR 0.79). DELIVER, also with EF >40%, found worsening heart failure or cardiovascular death in 16.4% versus 19.5% with dapagliflozin versus placebo (HR 0.82). In SOLOIST-WHF, patients with diabetes and recent worsening heart failure had fewer total cardiovascular deaths, hospitalizations and urgent heart-failure visits with sotagliflozin (HR 0.67).
Guidelines

Integration into clinical practice guidelines and recommendations

A 2022 comparison review reports ESC 2021 Class I, Level A dapagliflozin/empagliflozin for HFrEF and AHA/ACC/HFSA 2022 Class 1A SGLT2 inhibitors for symptomatic chronic HFrEF. Treatment combines ACEi/ARNi, beta-blockers, MRAs and SGLT2 inhibitors when tolerated and without contraindications. A 2025 review reports ESC 2023 Class I, Level A SGLT2 inhibitors for HFmrEF and HFpEF.
Aiming at harmony (2022 comparison review): ESC 2021

HFrEF: dapagliflozin/empagliflozin, I A

Beghini et al. (2025 review): ESC 2023 HFmrEF/HFpEF

HFmrEF/HFpEF: SGLT2i Class I, Level A

2025 review: ACC/AHA 2022 HF

Class I: symptomatic chronic HFrEF; IIa: HFpEF

Now

Current standard of care and ongoing research directions

A 2025 review describes SGLT2 inhibitors as effective HF treatment across the LVEF spectrum. DAPA-HF and EMPEROR-Reduced studied reduced EF; EMPEROR-Preserved and DELIVER enrolled EF >40%. SOLOIST-WHF tested sotagliflozin in diabetes with recent worsening heart failure, initiated before or shortly after discharge. These populations and endpoints matter when interpreting benefit.

Landmark Trials in This Story

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Related Evidence

Frequently Asked Questions

How did SGLT2 inhibitors go from diabetes drugs to heart failure treatment?+
EMPA-REG OUTCOME compared empagliflozin with placebo in high-risk type 2 diabetes and reported 38% lower cardiovascular mortality and 35% lower heart-failure hospitalization. DAPA-HF and EMPEROR-Reduced subsequently found heart-failure benefits with dapagliflozin and empagliflozin regardless of diabetes status.
Do SGLT2 inhibitors work in heart failure with preserved ejection fraction?+
Yes. In patients with EF >40%, EMPEROR-Preserved reduced cardiovascular death or heart-failure hospitalization with empagliflozin (HR 0.79). DELIVER reduced worsening heart failure or cardiovascular death with dapagliflozin (HR 0.82); worsening heart failure included urgent visits.
What are the landmark trials for SGLT2 inhibitors in heart failure?+
Key trials include EMPA-REG OUTCOME in high-risk type 2 diabetes; DAPA-HF and EMPEROR-Reduced in HFrEF; and EMPEROR-Preserved and DELIVER in patients with EF >40%. Their results should be read with their specific populations and endpoints.
Are SGLT2 inhibitors now guideline-recommended for heart failure?+
Yes. A 2022 comparison review reports ESC 2021 Class I, Level A dapagliflozin/empagliflozin in HFrEF and AHA/ACC/HFSA 2022 Class 1A SGLT2 inhibitors in symptomatic chronic HFrEF, when tolerated and without contraindications. A 2025 review reports ESC 2023 Class I, Level A SGLT2 inhibitors for HFmrEF and HFpEF.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026